EUVIMEDEUVIMED entdecken
Kohortenstudie

Risk of tuberculosis disease among patients with inflammatory bowel disease and inflammatory rheumatic disease treated with biologics in Denmark: a nationwide cohort study

Christian Kraef, Anne Ahrens Østergaard, Troels Lillebaek, Pernille Ravn, Andreas Fløe, Lone Larsen, Ada Colic, Inge Petersen, Isik Somuncu Johansen

Clinical Microbiology and Infection · 2025

DOI: 10.1016/j.cmi.2025.06.017 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Microbiology and Infection, 2025. Verfasst von Christian Kraef und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: christiankraef@gmail.com. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Rheumatic Diseases, Tuberculosis, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Region Syddanmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This nationwide retrospective cohort study estimates tuberculosis (TB) disease risk in adults and children with inflammatory bowel disease (IBD) and inflammatory rheumatic disease (IRD) treated with immunosuppressive biologics in Denmark, including temporal trends and risk stratification by TB infection status and country of birth. METHODS: Patients diagnosed with IBD or IRD from 1994 to 2018 were identified using the Danish National Patient Registry. Treatments with biologics and diagnoses of TB disease were determined through International Classification of Diseases, 10th Revision codes and microbiological records. Patient demographics, interferon-gamma release assay (IGRA) results, and drug use data were collected from national databases. Poisson regression was used to calculate TB incidence rates (IRs) and assess associations with biologic treatment, IGRA status, country of birth, age, and sex. RESULTS: During 553 551 person-years of follow-up, 117 patients with TB disease were identified, with 71 cases occurring in biologic-naïve patients and 46 in biologic-treated individuals. The crude IR was 39.3 of 100 000 person-years (95% CI, 29.4-52.4) for biologic-treated individuals, compared with 12.4 of 100 000 person-years (95% CI, 9.2-16.8) for naive patients, yielding an IR ratio (IRR) of 3.2 (95% CI, 2.0-4.9). The TB risk was higher in IGRA-positive patients (vs. negative, IRR 45.0, 95% CI, 12.0-168.2) and those born in intermediate (vs. low-incidence country, IRR 7.9, 95% CI, 3.3-18.9) or high TB incidence countries (vs. low-incidence country, IRR 7.5, 95% CI, 2.9-19.1). DISCUSSION: The elevated risk of TB disease in patients with IRD and IBD treated with biologics is strongly associated with IGRA positivity and country of birth. These findings highlight the importance of comprehensive baseline TB risk assessment and patient education in combination with personalized follow-up to guide preventive strategies in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesRheumatic DiseasesTuberculosisBiological ProductsHumansDenmarkMaleFemaleAdultRetrospective StudiesMiddle AgedIncidenceChildAdolescentYoung AdultAgedRisk FactorsChild, PreschoolInterferon-gamma Release Tests

Stichwörter der Autor:innen

BiologicsImmunosuppressionInflammatory bowel diseaseInflammatory rheumatic diseaseNationwide cohortTuberculosis

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark. Electronic address: christiankraef@gmail.com.
  • Department of Infectious Diseases, Odense University Hospital and Mycobacterial Centre for Research Southern Denmark (MyCRESD), Odense, Denmark; Research Unit of Infectious Diseases, Department of Clinical Research, Uni…
  • International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark; Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Department of Medicine, Infectious Disease Section, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark.
  • Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark; Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University,…

Förderung

  • Region Syddanmark

Zitieren

APA

Kraef, C., Østergaard, A. A., Lillebaek, T., Ravn, P., Fløe, A., Larsen, L., Colic, A., Petersen, I., & Johansen, I. S. (2025). Risk of tuberculosis disease among patients with inflammatory bowel disease and inflammatory rheumatic disease treated with biologics in Denmark: a nationwide cohort study. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2025.06.017

Vancouver

Kraef C, Østergaard AA, Lillebaek T, Ravn P, Fløe A, Larsen L, et al. Risk of tuberculosis disease among patients with inflammatory bowel disease and inflammatory rheumatic disease treated with biologics in Denmark: a nationwide cohort study. Clinical Microbiology and Infection. 2025. doi:10.1016/j.cmi.2025.06.017

BibTeX
@article{Kraef2025,
  author = {Kraef, Christian and Østergaard, Anne Ahrens and Lillebaek, Troels and Ravn, Pernille and Fløe, Andreas and Larsen, Lone and Colic, Ada and Petersen, Inge and Johansen, Isik Somuncu},
  title = {Risk of tuberculosis disease among patients with inflammatory bowel disease and inflammatory rheumatic disease treated with biologics in Denmark: a nationwide cohort study},
  journal = {Clinical Microbiology and Infection},
  year = {2025},
  doi = {10.1016/j.cmi.2025.06.017}
}
Kostenlos starten →